A new study found that spending on GLP-1 medications such as Ozempic, Wegovy and Zepbound surged to $5.8 billion in 2022 ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

Meghan Trainor revealed her transformation journey involves a mix of lifestyle changes, working with a dietitian, and using ...

Patients without diabetes using GLP-1RAs are less likely to develop glaucoma compared with those who use other weight loss therapies.

Meghan Trainor has given the type 2 diabetes drug Mounjaro a special shout out when addressing her recent weight loss ...

Eli Lilly ( NYSE: LLY) on Tuesday will file lawsuits against two companies that the drug giant is accusing of mass ...

The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4 ...

In patients with heart failure with preserved ejection fraction and obesity, tirzepatide improved clinical outcomes compared ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new study says.

After starting 2024 strong, Eli Lilly (NYSE: LLY) did not perform well in the second half of last year. Its financial results ...

Anecdotal reports suggest drugs like Ozempic may curb not just appetite but also impulsive or addictive behaviour, hinting at ...